EUROPEAN PATENT APPLICATION

Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

Priority: 03.06.2008 EP 08157521
26.02.2009 EP 09153804

Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
0975739.8 / 2 266 240

Applicant: Université de Liège
4031 Angleur (BE)

Inventors:
• HENROTIN, Yves
  4000 Liège (BE)
• GHARBI, Myriam
  4000 Liège (BE)
• DEBERG, Michele
  4000 Liège (BE)
• DE PAUW, Edwin
  4000 Liège (BE)

Remarks:
This application was filed on 11-08-2015 as a divisional application to the application mentioned under INID code 62.

BIOMARKER FOR OSTEOARTHRITIS AND USE THEREOF

The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.

Figure 1A

Figure 1B
Description

[0001] The present invention relates to a biomarker for osteoarthritis and/or other ageing-related diseases. In particular, the invention relates to a method of diagnosing osteoarthritis, and/or other ageing-related diseases, by determining the level of a biomarker in a biological sample. The invention also relates to the use of a biomarker found in biological sample to monitor the efficacy of a treatment for osteoarthritis, and/or other ageing-related diseases, and to determine the prognosis for an individual diagnosed with osteoarthritis, and/or other ageing-related diseases.

[0002] Osteoarthritis is a progressive disorder characterized by destruction of articular cartilage and by subchondral bone and synovial changes. Currently the diagnosis of osteoarthritis is based on clinical and radiographic changes which occur late during disease progression. More specifically, diagnosis is based on cartilage integrity, which as articular cartilage is invisible on radiographs must be assessed indirectly from the spacing between subchondral bone ends in a joint. This method does not allow detection of early structural damage, and is cumbersome to use in daily practice.


[0004] There therefore remains a need for a simple, rapid and effective method for the diagnosis of osteoarthritis and/or other ageing-related diseases, and/or to monitor the efficacy of treatments for osteoarthritis and/or other ageing-related diseases, and/or to determine the prognosis for a patient diagnosed with osteoarthritis and/or other ageing-related diseases.

[0005] The present invention provides a method for (i) diagnosing osteoarthritis and/or another ageing-related disease, (ii) determining the prognosis for a patient with osteoarthritis and/or another ageing-related disease, and (iii) monitoring the efficacy of a treatment for osteoarthritis and/or another ageing-related disease, using readily available biological samples and allow for rapid and cost effective use.

[0006] Reference herein to "other ageing-related diseases" or "another ageing related disease" is intended to refer to one or more diseases related to ageing which may include one or more of osteoporosis, macular degeneration and other degenerative diseases.

[0007] According to one aspect, the present invention provides a method of determining the osteoarthritis status of a subject, and/or the status of another ageing-related disease in a subject, comprising the steps of:

(i) determining the concentration in a biological sample of a free fragment comprising the same or substantially the same amino acid sequence as Seq ID no:1 or a fragment thereof;
(ii) comparing the free fragment concentration determined in step (i) with one or more reference values.

[0008] Reference herein to "free fragment" is intended to refer to a polypeptide, a peptide or otherwise released from mammalian fibulin-3 molecule by an oxidative or enzymatic processing. A free fragment is different from the native protein by its structure and configuration and may undergo modification such as phosphorylation, glycosylation or any other post-traducional modification resulting of a pathological mechanism. The free fragment according to the invention contributes to the identification of the pathologic status of osteoarthritis or osteoporotic patient.

[0009] According to another aspect, the present invention provides a method of diagnosing osteoarthritis and/or another ageing-related disease in a subject, comprising the steps of:

(i) determining the concentration in the sample of a free fragment comprising the same or substantially the same amino acid sequence as Seq ID no:1 or a fragment thereof;
(ii) comparing the free fragment concentration determined in step (ii) with one or more reference values.

[0010] According to yet another aspect, the present invention provides a method of determining the prognosis for a subject with osteoarthritis and/or another ageing-related disease, comprising the steps of:

(i) determining the concentration in the sample of a free fragment comprising the same or substantially the same amino acid sequence as Seq ID no:1 or a fragment thereof;
(ii) comparing the free fragment levels determined in step (i) with one or more reference values.

[0011] According to a further aspect, the present invention provides a method of determining the efficacy of a treatment
for osteoarthritis and/or another ageing-related disease in a subject, comprising the steps of:

(i) determining the concentration in a biological sample of a free fragment comprising the same or substantially the same amino acid sequence as Seq ID no: 1 or a fragment thereof;
(ii) administering a treatment for osteoarthritis and/or another ageing related disease to the subject;
(iii) determining after treatment the concentration in another biological sample of a free fragment comprising the same or substantially the same amino acid sequence as Seq ID no: 1 or a fragment thereof;
(iv) comparing the free fragment concentrations determined in step (i) and step (iii) with one another, and optionally with one or more reference values.

[0012] Preferably, in any method of the invention, the concentration of a free fragment with the same sequence as the sequence of Seq ID no: 1 is determined. Alternatively, the concentration of a free fragment with a sequence substantially the same as the sequence of Seq ID no: 1 may be determined.

[0013] Alternatively, the concentration of a peptide fragment having a sequence the same, or substantially the same, as part of the sequence of Seq ID no: 1 may be determined. The peptide fragment may have a sequence the same or substantially the same as one end of the sequence of Seq ID no: 1. Alternatively, the peptide fragment may have a sequence the same or substantially the same as an internal part, that is, not including either end, of the sequence of Seq ID No: 1. Preferably the peptide fragment is at least 5, preferably at least 10, preferably at least 20, more preferably at least 30 or more amino acids long.

[0014] Preferably if the concentration of a fragment having a sequence the same, or substantially the same as part of the sequence of Seq ID no: 1 is determined, the fragment represents an epitope within the sequence of Seq ID no: 1.

[0015] An epitope is a binding site of an antibody on an antigen. In a peptide antigen, generally a linear epitope will be at least about 7 amino acids in length, and may be at least 8, at least 9, at least 10, at least 11, at least 12, at least 14, at least 16, at least 18, at least 20, at least 22, at least 24, or at least 30 or more amino acid residues in length. However, antibodies may also recognise conformational determinants formed by non-contiguous residues on an antigen, and an epitope can therefore require a larger fragment of the antigen to be present for binding, e.g. a domain.

[0016] Reference herein to "a sequence substantially the same as" all or part of the sequence of Seq ID no: 1, refers to a free fragment with a sequence which has at least 80%, preferably at least 90%, more preferably at least 95% or 98%, sequence identity with all or part of the sequence of Seq ID No: 1. Preferably the peptide has a sequence the same or substantially the same as at least about 5, 10, 15, 20, 25, 30, 35, 40, 45 or more consecutive amino acids of the sequence of Seq ID No: 1. Preferably, the free fragment has a sequence the same, or substantially the same, as the entire sequence of Seq ID No: 1.

[0017] Homology or sequence identity of two or more amino acid sequences can be measured by using a homology scoring algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool). Alternatively, the UWGCC Package provides the BESTFIT program which can be used to calculate sequence identity between two or more sequences (e.g. used on its default setting) (Devereux et al (1984) Nucleic Acids Research 12 p387-395).

[0018] The sequence of Seq ID no: 1 represents a fragment of the fibulin-3 protein. The fragment may be a degradation product of fibulin-3.

[0019] In any method of the invention the free fragment comprising a sequence the same or substantially the same as the sequence of Seq ID no: 1 or a part thereof is preferably differentially present in the sample from a subject with osteoarthritis or another ageing-related disease compared to a normal subject.

[0020] A free fragment comprising the same or substantially the same sequence as Seq ID no: 1 or a fragment thereof, which is measured in step (i) and/or step (iv) in any method of the invention, is also referred to herein as the biomarker or the biomarker peptide.

[0021] Reference to the "osteoarthritis status" or to the "status of an ageing-related disease" refers to any distinguishable manifestation of osteoarthritis or an ageing-related disease, including diseased and non-diseased. For example, osteoarthritis status includes, without limitation, the presence or absence of osteoarthritis in a subject, the risk of a subject developing osteoarthritis, the stage of the disease, the progression of the disease, and the effectiveness or response of a subject to a treatment for osteoarthritis.

[0022] Any method of the invention may be used in conjunction with the assessment of clinical symptoms and/or imaging results and/or the concentration of one or more other biomarkers.

[0023] Preferably all methods of the invention are carried out in vitro.

[0024] The biological sample may comprise urine, whole blood, blood serum, blood plasma, synovium, sweat, cerebrospinal fluid, mucous, saliva, lymph, bronchial aspirate, milk and the like. Preferably the biological sample is urine.

[0025] Biological sample, such as urine, have the advantage of being abundant and easily accessible.

[0026] A further advantage of using a biological sample, compared to a tissue such as cartilage, is that the progression of osteoarthritis or another ageing-related disease, and/or the therapeutic effect of a treatment, may be monitored by
taking and testing samples as often as necessary without the need for invasive procedures.

[0027] The concentration of the biomarker peptide in a sample may be determined by any suitable assay. A suitable assay may include one or more of the following methods, an enzyme assay, an immunoassay, mass spectrometry, HPLC, electrophoresis or an antibody microarray, or any combination thereof. If an immunoassay is used it may be an enzyme linked immunoassay (ELISA), a sandwich assay, a competitive assay, a radioimmunoassay, a Western Blot, an immunoassay using a biosensor, an immunoprecipitation assay, an agglutination assay, a turbidity assay or a nephelometric assay. If mass spectrometry is used it may be Matrix Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry.

[0028] Preferably the concentration of the biomarker peptide is determined using an immunoassay which uses one or more antibodies directed to the specific biomarker peptide to determine the concentration of the biomarker peptide in the sample.

[0029] If one or more antibodies are used to determine the concentration of a biomarker peptide in a sample the one or more antibodies may be synthetic, monoclonal, polyclonal, oligoclonal, bispecific, chimeric and/or humanised.

[0030] One or more of the antibodies used may comprise a tag or a label. The tag or label may be selected from the group comprising a radioactive, a fluorescent, a chemiluminescent, a dye, an enzyme, or a histidine tag or label, or any other suitable label or tag known in the art.

[0031] Preferably the reference value, to which the determined concentration of the biomarker peptide is compared, is the concentration of the same peptide in one or more "normal" subjects that do not have any detectable osteoarthritis and/or other age-related disease, or any clinical symptoms of osteoarthritis and/or other age-related disease, and have so called "normal values" of the biomarker peptide.

[0032] Alternatively, the reference value may be a previous value for the biomarker peptide obtained from a specific subject. This kind of reference value may be used if the method is to be used to monitor progression of osteoarthritis and/or another age-related disease, or to monitor the response of a subject to a particular treatment.

[0033] When the determined concentration of the biomarker is compared with a reference value, an increase or a decrease in the concentration of the biomarker may be indicative of the osteoarthritis status, and/or the status of another age-related disease, in the subject.

[0034] More specifically an increase or a decrease in the concentration of the biomarker may be indicative, or diagnostic, of osteoarthritis in the subject. An increase in the concentration of the biomarker, preferably of a free fragment with the sequence of Seq ID no:1, in a sample may be diagnostic of osteoarthritis.

[0035] Preferably an at least about 2 fold or more increase in the concentration of a free fragment with the sequence of Seq ID no:1, or with a sequence substantially the same as Seq ID no:1, or a fragment thereof, in a sample from a subject compared to a reference sample from a normal subject is diagnostic of osteoarthritis.

[0036] The method of the invention may also be used to monitor osteoarthritis progression, and/or the progression of another age-related disease, in a subject. Furthermore, the method of the invention may be used to monitor the efficacy of a treatment for osteoarthritis, and/or another age-related disease, following administration of the treatment to a subject. Efficacy of a treatment may be monitored by analysing samples taken from a subject at various time points following initiation of the treatment. By monitoring changes in the concentration of the biomarker peptide over time and comparing these concentrations to normal and/or reference values, efficacy of the treatment may be determined. In this case, reference concentrations may include the concentration of the biomarker peptide in the subject when a sample was first taken and analysed, or the concentration of the biomarker peptide in the subject when a sample was last taken, or both.

[0037] The subject in any method of the invention may be mammal, and is preferably a human, but may alternatively be a monkey, ape, dog, cow, gallus or rodent.

[0038] According to another aspect of the invention there is provided a kit for use in determining the osteoarthritis status, or the status of another age-related disease, in a subject, wherein the kit comprises at least one agent for determining the concentration of a free fragment comprising the same or substantially the same amino acid sequence as the sequence of Seq ID No:1, or a part thereof, in a biological sample.

[0039] The kit may be used to diagnose osteoarthritis and/or another age-related disease in a subject. The kit may alternatively be used to monitor disease progression or the efficacy of a treatment administered to a subject with osteoarthritis and/or another age-related disease.

[0040] The agent may be an enzyme, an antibody, a protein probe, a metabolite or any other suitable composition.

[0041] The agent for determining the concentration of the free fragment is preferably labelled. The kit may also comprise means for detecting the label.

[0042] The kit may comprise one or more capture agents for capturing the free fragment comprising the same or substantially the same amino acid sequence as the sequence of Seq ID No:1, or a part thereof, in a biological sample. The capture agent may be one or more antibodies. The capture agent may be an antibody according to an aspect of the invention.

[0043] The kit may comprise two antibodies for use in a sandwich assay to determine the concentration of a free
fragment comprising the same or substantially the same amino acid sequence as the sequence of Seq ID No:1, or a part thereof. Preferably the kit comprises two antibodies, each directed to a different epitope on the free fragment comprising the same or substantially the same amino acid sequence as the sequence of Seq ID No:1, or a part thereof. One antibody is preferably the capture antibody, and the other antibody is preferably a detection antibody and may be labelled to allow its detection.

[0044] The capture agent may be attached to a solid support. The solid support may be a chip, a microtitre plate, a bead or a resin.

[0045] The kit may comprise instructions for suitable operational parameters in the form of a label or separate insert. The instructions may inform a user about how to collect the sample, and/or how to wash the capture agent.

[0046] The kit may comprise samples of the biomarker peptide to be detected. The samples of the biomarker peptide may be used as a standard for calibration and comparison. The kit may also comprise instructions to compare the concentration of the biomarker peptide detected in a sample with a calibration sample or chart. The kit may also include instructions indicating what concentration of the biomarker peptide is diagnostic of osteoarthritis and/or another ageing-related disease.

[0047] According to a yet further aspect, the invention provides the use of the determination of the concentration of the biomarker peptide in a sample of biological sample as a means of assessing the osteoarthritis status in a subject or as a means of assessing the status of another ageing-related disease in a subject.

[0048] According to a yet further aspect, the present invention provides the use of a biological sample, such as urine, as a source of at least one biomarker for use in determining the prognosis of osteoarthritis progression and/or another ageing-related disease, and/or for diagnosing osteoarthritis and/or another ageing-related disease, and/or for monitoring the effect of a treatment for osteoarthritis and/or another ageing-related disease.

[0049] According to another aspect of the invention provides a free fragment which comprises the same, or substantially the same, amino acid sequence as the amino acid sequence of Seq ID NO: 1, or a part thereof, or its amide, or a salt thereof.

[0050] Preferably the free fragment of the invention has a sequence the same as that of Seq ID No:1.

[0051] According to a further aspect, the invention provides a polynucleotide encoding a free fragment according to the invention. Preferably, the polynucleotide is a DNA molecule.

[0052] According to a yet further aspect the invention provides a recombinant vector, which comprises a polynucleotide of the invention.

[0053] According to another aspect the invention provides a transformant, which is transformed with the recombinant vector of the invention.

[0054] In a further aspect, the invention provides the use of a free fragment according to the invention in the manufacture of an antibody.

[0055] It a yet further aspect, the invention provides an antibody specific for a free fragment according to the invention. In particular, the invention provides an antibody specific for a free fragment having the sequence of Seq ID NO: 1.

[0056] An antibody according to the invention may be synthetic, monoclonal, polyclonal, oligoclonal, bispecific, chimeric or humanised. The antibody may be complete or a fragment thereof, such as, Fv, Fab and F(ab)2 fragments. Methods of generating antibodies are well known in the art, and may include immunisation of suitable animals, such as, a rabbit, mouse, sheep or goat, with the peptide of interest (or an immunogenic fragment thereof) or recombinant techniques.

[0057] The skilled man will appreciate that preferred features of any one embodiment and/or aspect of the invention may be applied to all other embodiments and/or aspects of the invention.

[0058] Embodiments of the invention will now be described merely by way of examples with reference to the accompanying figures in which:

**Figure 1A** - shows an enlargement of a portion of a 2D-DIGE map from osteoarthritis (OA) subjects (right) and non-osteoarthritis (NO) subjects (left).

**Figure 1B** - shows a representation of spot volume variation between OA subjects (right) and NO subjects (left).

**Figure 2** - shows a graphic view of fibulin-3 abundance modification based on the spot volume increase shown in Figure 1B.

**Figure 3A** - shows the result of a mass spectrometry analysis of tryptic fragments of the peptide of fibulin-3 recovered from spot 352 detailed in Figures 1A, Figure 1B and Figure 2.

**Figure 3B** - shows the sequence of human fibulin-3 containing the fragments shown in Figure 3A.

**Figure 4** - shows the modular domain structure of the fibulin proteins.
Figure 5 - shows the protein sequence of SEQ ID No. 1.

Figure 6 - shows the protein sequence of SEQ ID No. 2.

Figure 7A - shows an enlargement of a portion of a 2D-DIGE map from osteoarthritis (OA) subjects (Cy3, left) and osteoporosis (OP) subjects (Cy5, right).

Figure 7B - shows a graphic view of fibulin-3 abundance modification based on the spot volume increase shown in Figure 7A.

Figure 8 - shows an enhanced portion of 2D-DIGE gel obtained from proteins extracted from patients with severe osteoarthritis (OA), patients with osteoporosis (OP) and controls younger than 30 years (CTRL).


[0060] In the examples, 2D-DIGE was used to study the protein expression profiles in urine samples from subjects with serious osteoarthritis or osteoporosis and from healthy young subjects. Proteins in the samples to be compared were labelled with either Cy3 or Cy5 CyDye DIGE Flours. The Cy2 CyDye DIGE Fluor was used to label a pooled sample comprising equal amounts of each of the samples within the study, and this used as an internal standard. The use of this internal standard ensured that all proteins present in the samples were represented, assisting both inter- and intra-gel matching.

MATERIALS AND METHODS

Urine samples preparation

[0061] Urine samples were collected from 10 women undergoing hip replacement surgery due to severe osteoarthritis. Control samples were obtained from 5 healthy women (25.6 ± 2.6 years) without articular degeneration. The urine samples were concentrated 100x by ultracentrifugation on Amicon Ultra-15 (Millipore, USA). Proteins were purified by precipitation using PlusOne 2D Clean-up kit (GE Healthcare, Sweden). Albumin depletion from urine samples was performed using affinity columns according to the Montage Albumin Deplete Kit (Millipore, USA) manual utilisation.

Labelling of proteins with Cy3 and Cy5 dyes

[0062] In all experiments, the purified proteins were labelled on lysine residues with Cy3 or Cy5 CyDye DIGE Flours. The samples were minimal labelled which means that the ratio of dye to protein used was such that each protein molecule was labelled with only one dye molecule. Three gels were made as shown in Table 1. Proteins from different samples were labelled with Cy3 or Cy5 and loaded on the same gel. On the first and second gels, proteins from normal (NO) samples were labelled with Cy3 CyDye DIGE Fluor whereas protein from osteoarthritis (OA) samples were labelled with Cy5 CyDye DIGE Fluor. Conversely, on the third gel, proteins from NO samples were labelled with Cy5 CyDye DIGE Fluor and proteins from OA samples were labelled with Cy3 CyDye DIGE Fluor. An internal standard (MIX) comprising equal amounts of NO and OA samples was labelled with Cy2 CyDye DIGE Fluor and loaded on each gel.

<table>
<thead>
<tr>
<th></th>
<th>Gel 1</th>
<th>Gel 2</th>
<th>Gel 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cy3</td>
<td>NO</td>
<td>NO</td>
<td>OA</td>
</tr>
<tr>
<td>Cy5</td>
<td>OA</td>
<td>OA</td>
<td>NO</td>
</tr>
<tr>
<td>Cy2</td>
<td>MIX</td>
<td>MIX</td>
<td>MIX</td>
</tr>
</tbody>
</table>

Two-dimensional electrophoresis

[0063] Protein samples (37.5 µg) labelled with Cy3, Cy5 or Cy2 DIGE Fluor were separated by 2D electrophoresis using an IEF (isoelectric focusing) buffer (8 M urea, 2% CHAPS, 0.5% immobilized pH gradient [IPG] buffer, 1% DTT, and trace of bromophenol blue) which was loaded into an immobiline DryStrip (pH 3-10 NL, 24 cm) (GE Healthcare, Sweden). The first dimension isoelectric focusing was performed for 70,000 Vhr using a Protean IEF Cell (Biorad) at
20°C. Next, the gels were equilibrated for 12 minutes in equilibration buffer I (375 mM Tris-Cl [pH 8.8], 6 M urea, 20% glycerol, 2% SDS, and 130 mM DTT) and II (375 mM Tris-Cl [pH 8.8], 6 M urea, 20% glycerol, 2% SDS, and 135 mM IAA). The second dimension was run according to the Ettan DALTSix Electrophoresis Unit operating manual (GE Healthcare, Sweden). A 12.5% SDS-polyacrylamide slab gel (24 cm) was used for the second-dimension gel electrophoresis. The IPG strips were placed on the surface of the second-dimension gel. The gels were then placed in SDS electrophoresis buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS) and run overnight at 1.5 W per gel.

[0664] Gels were scanned while still between two low-fluorescence glass plates using a Typhoon 9400 fluorescent scanner and saved in .gel format using ImageQuant software (GE Healthcare, Sweden). The excitation wavelengths for Cy3 and Cy5 are 550 nm and 645 nm, and the emission wavelengths are 570 nm and 670 nm for Cy3 and Cy5, respectively. The excitation/emission wavelength of Cy2 is around 489/505 nm. Image analysis was performed on DeCyder™ software (GE Healthcare, Sweden). Interesting spots with differential fluorescent intensity between Cy3 and Cy5 were picked out the gel, after post-staining with Coomassie Blue, in order to allow protein identification.

[0665] DeCyder 2D v6.5 software (GE Healthcare, Sweden) was used for the simultaneous comparison of abundance changes across sample groups. The DeCyder differential in-gel analysis (DIA) module generated ratios for each protein "spot" by comparing Cy3 and Cy5 signals to the Cy2 control signal. The DeCyder biological variation analysis module matched all protein spot maps from the gels and normalized the DIA-generated Cy3:Cy2 and Cy5:Cy2 ratios relative to the Cy2 signals for each resolved feature separately. This enabled the calculation of average abundance changes across all three samples within each test group, and the application of univariate statistical analyses (Student's t-test, ANOVA).

Proteins identification

[0666] Protein spots were cut out of the polyacrylamide gel and washed twice for 5 minutes with an ammonium hydrogen carbonate (50 mM)-acetonitrile mix (1:1). Gel spots were incubated in dithiothreitol (10 mM), NH₄HCO₃ (50 mM), for 40 min in a 56°C water bath. Proteins in the gel spots were alkylated for 1h in the dark with iodoacetamide (55 mM) in NH₄HCO₃ (50 mM). The gel spots were then washed twice with an ammonium hydrogen carbonate (50 mM)-acetonitrile mix (1:1), dehydrated with acetonitrile, and then dried for 15 minutes at room temperature. The gel spots were then rehydrated for 10 minutes on ice with modified trypsin (10 ng/μl) in NH₄HCO₃ (25 mM) and then incubated overnight at 37°C. Hydrolysis of peptides was stopped in TFA (1%)-ACN (5%) solution. The gel spots were then sonicated twice for 1 minute in order to release protein fragments out of the isolated gel spots. Protein fragments in solution were freeze-dried. The identity of proteins was determined by tandem mass spectrometry (MS-MS spectrometry). The Mowse score (Pappin et al (1993) Curr Biol Jun 1;3(6):327-32) gave the fidelity of identification.

Results

[0667] Proteins isolated from the urine samples and labelled with Cy3 or Cy5 were separated by two-dimensional electrophoresis. The first separation was performed with an isoelectric focusing range of pH 3-10 NL and a load of 37.5 μg of protein. 372 spots of proteins were matched between all gels. Spots with a modification of intensity between OA and NO with a ratio superior to 1.5 (t-test; p < 0.05) were selected for protein identification using mass spectrometry. Table 2 shows the results of analysis of these spots, and details the size of the spot, the Mowse score (which is -10 log (P) where P is the probability that the observed match is a random event), the abundance ratio, the name of the protein identified in the spot and the accession number for the identified protein in the Swiss Prot database.

<table>
<thead>
<tr>
<th>Spot n°</th>
<th>Sequence coverage (%)</th>
<th>Mowse score</th>
<th>Abundance ratio (OA/NO)</th>
<th>Protein description</th>
<th>Swiss-Prot Accession</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>9</td>
<td>390</td>
<td>1.83</td>
<td>Poly-Ig receptor (PIGR)</td>
<td>P01833</td>
</tr>
<tr>
<td>43</td>
<td>5</td>
<td>159</td>
<td>1.6</td>
<td>Poly-Ig receptor (PIGR)</td>
<td>P01833</td>
</tr>
<tr>
<td>75</td>
<td>10</td>
<td>340</td>
<td>-1.68</td>
<td>Transferrin</td>
<td>P02787</td>
</tr>
<tr>
<td>219</td>
<td>11 6</td>
<td>334 55</td>
<td>-1.7</td>
<td>Kininogen-1 precursor Alpha 1 antitrypsin (A1AT)</td>
<td>P01042 P01009</td>
</tr>
<tr>
<td>222</td>
<td>15 7</td>
<td>349 99</td>
<td>-1.64</td>
<td>Kininogen-1 precursor A1AT</td>
<td>P01042 P01009</td>
</tr>
<tr>
<td>223</td>
<td>13 16</td>
<td>405 311</td>
<td>-1.89</td>
<td>Kininogen-1 precursor A1AT</td>
<td>P01042 P01009</td>
</tr>
</tbody>
</table>
As can be seen from Table 2, various proteins with significant changes in concentration in samples from osteoarthrits compared to samples from normal subjects were identified. Some of the proteins identified are known to be implicated in the inflammatory process, for example, the kinogen precursor or alpha-1-antitrypsin. This observation coincides with the pathology of osteoarthrits.

A significant increase in the concentration of a specific fibulin-3 fragment was observed in osteoarthrits subjects compared to normal subject, as shown in Table 2 and Figures 1A and 1B. In Figure 1A there is shown an enlargement of the area around spot 352 (indicated by one side of the double headed arrow) on the 2D-DIGE map of proteins extracted from urine from osteoarthrits subjects (right) compared to normal subjects (left). Spot 352 was shown by mass spectrometry to contain a fibulin-3 fragment. In Figure 1B the same spot (spot 352) is represented by volume variation of the spot (indicated by the other head of the double headed arrow, equivalent to the spot of Figure 1A) between samples from OA subjects (right) and NO subjects (left). A graphic view of the abundance modification based on the spot 352 volume increase is also shown in Figure 2.

Tryptic fragments from spot 352 were identified by mass spectrometry analysis as shown in Figure 3A. These fragments were identified as being fragments from the protein fibulin-3, as shown in Figure 3B. Figure 3B shows the protein sequence derived by the translation of the mRNA of human fibulin-3 and in bold the specific sequence identified by mass spectrometry. Each tryptic fragment studied was given a score which is - 10 log (P), where P is the probability that the observed match is a random event. Individual ion scores > 50 indicate identity or extensive homology. In the case of Figure 3A the tryptic peptides scored 58 and 72 respectively indicating extensive homology.

In addition to the experiments comparing OA and NO subjects, further studies were undertaken to compare OA and osteoporosis (OP) subjects. In these studies urine samples obtained from four women with serious osteoporosis. Three gels were made, as shown in Table 3, to compare the OA and OP subjects. Proteins from different samples were labelled with Cy3 or Cy5 CyDye DIGE Fluor and loaded on gels as indicated in Table 3. An internal standard (MIX) comprising equal amounts of OA and OP samples was labelled with Cy2 CyDye DIGE Fluor and loaded on each gel. The first separation was performed with an isoelectric focusing range of pH 4-7 and a load of 37.5 µg of protein.
EP 2 975 411 A1

(continued)

<table>
<thead>
<tr>
<th>Gel 1</th>
<th>Gel 2</th>
<th>Gel 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cy5</td>
<td>OP</td>
<td>OP</td>
</tr>
<tr>
<td>Cy2</td>
<td>MIX</td>
<td>MIX</td>
</tr>
</tbody>
</table>

[0072] Analysis of the gels shows that the spot containing the fibulin-3 fragment (as described with reference to Figures 3A and 3B) shows a decrease of abundance in OP samples compared to OA samples with a ratio of 6.72. These results are illustrated in Figures 7A and 7B.

[0073] In a second experiment, proteins extracted from urine of osteoarthritic (OA) and control (NO) populations used in the initial experiment (described with reference to Figures 1 to 6) and from the urine of osteoporotic patients (OP) (described with reference to Figures 7A and 7B) were compared. Five gels were made as shown in Table 4. Proteins from different samples were labelled with Cy3 or Cy5 and loaded on the same gel. An internal standard (MIX) comprising equal amounts of NO, OA and OP samples was labelled with Cy2. CyDye DIGE Fluo and loaded on each gel. The first separation was performed with an isoelectric focusing range of pH 4-7 and a load of 37.5 μg of protein.

<table>
<thead>
<tr>
<th>Gel 1</th>
<th>Gel 2</th>
<th>Gel 3</th>
<th>Gel 4</th>
<th>Gel 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cy3</td>
<td>OA</td>
<td>OP</td>
<td>NO</td>
<td>NO</td>
</tr>
<tr>
<td>Cy5</td>
<td>OP</td>
<td>OA</td>
<td>OA</td>
<td>OP</td>
</tr>
<tr>
<td>Cy2</td>
<td>MIX</td>
<td>MIX</td>
<td>MIX</td>
<td>MIX</td>
</tr>
</tbody>
</table>

[0074] Analysis of the five gels showed that spots containing the fragment of fibulin-3 (as described with reference to Figures 3A and 3B) show an abundance modification with a ratio comprised between 4-8 for OA/NO comparison and 4-12 for OP/OA comparison, depending on the spot containing the fragment. Indeed, we have identified five different forms of the fibulin-3 which differently discriminate osteoarthritic and osteoporotic patients as illustrated in figure 8.

[0075] The appearance of several spots containing fragments of fibulin-3 suggests that the protein is present in various forms in the urinary proteome. The sequence could be modified specifically by phosphorylation, glycosylation or other post-translational modifications resulting of a pathophysiological mechanism. All the identified forms are increased in OA samples compared to OP and NO samples. However, some forms appear to be more increased regarding the spot observed and could be more concerned by the pathologic process. Selected fragment discriminates patients with osteoarthritic from those with osteoporosis. This could not be identified by a person skilled in the art.

[0076] This data shows that the increased abundance of the fragment of fibulin-3 is a specific event occurring in osteoarthritic disease. Furthermore, a decrease in the level of this protein is seen in samples from subjects with osteoporosis samples compared to those from subjects with osteoarthritis. Note that different ratios were found between multiple experiments because the internal standard was changed for each of them.

[0077] In figure 8, Proteins were separated on a linear pH gradient (pH 4-7) IPG strip, followed by a 12.5% SDS-PAGE. Selected spots ( ) contain fragments of fibulin-3 identified by mass spectrometry. Modified ratio of fibulin-3 content is annotated under the corresponding spot.

[0078] Fibulins are a family of five extracellular matrix proteins characterized by modular domain structures as depicted in Figure 4. The general fibulin modular domain structure comprises tandem arrays of epidermal growth factor-like (EGF-like) modules (domain II, represented by circles) and a C-terminal fibulin-type module (domain III, represented by rectangles). Some of the EGF-like modules possess a consensus motif for calcium binding (cBEFG-like module represented by circles with black dots). Fibulin-1 and fibulin-2 comprise anaphylatoxin-like modules (domain I, represented by diamonds). Domain N, which is unique to fibulin-2, can be subdivided into a Cys-rich segment (Na) and a Cys-free segment (Nb). Fibulin-3, fibulin-4, and fibulin-5 have a modified cBEFG-like module at their N-terminus. This modified cBEFG-like module has an extra Cys\(^4\) -Cys\(^5\) loop at the beginning of the module and a long linker region between Cys\(^3\)-Cys\(^5\) and Cys\(^5\)-Cys\(^8\) loops. The residues between Cys\(^4\) and Cys\(^5\) are shown in parentheses. Four different alternative splice variants are reported for human fibulin-1, shown as variants A-D, and the numbers in parentheses indicate residues of domain III.

[0079] Fibulin-1 (703 AA; 77.2 kDa) and Fibulin-2 (1184 AA; 126.5 kDa) are localized in basement membranes, elastic fibers, and other connective tissue structures. Fibulin-4 (443 AA; 49.4 kDa) was identified through its sequence homology to fibulin-1, fibulin-2, and fibulin-3 and independently as a protein interacting with a mutant form of the tumor suppressor protein p53. Fibulin-5 (48 AA; 50.2 kDa) was first characterized as a gene strongly expressed in large blood vessels.
during embryonic development and highly up-regulated upon vascular injury.

[0080] Fibulin-3 is also known as EFEMP1 protein and has SWISS-PROT accession number Q12805. Fibulin-3 is a protein comprising 493 amino acids and has a molecular weight of about 54.6 kDa. Fibulin-3 was originally identified by subtractive cDNA cloning from a Werner syndrome fibroblast library and shown to be expressed at increased levels in serum-deprived fibroblasts. As with all other fibulins, fibulin-3 is present in blood vessels of different sizes and is capable of inhibiting vessel development and angiogenesis both in vitro and in vivo. Fibulin-3 is expressed in cartilage and bone structures during development and may play a role in the skeletal system. Fibulin-3 is known to be intimately associated with TIMP-3, an inhibitor of metalloproteinase involved in the pathogenesis of osteoarthritis (Klenotic et al., J Biol Chem, 2004. 279(29): p. 30489-73; Sahebjam et al., Arthritis Rheum, 2007. 56(3): p. 905-9; Kevorkian et al., Arthritis Rheum, 2004. 50(1): p. 131-41). The results presented herein show that the fibulin-3 fragment described with reference to Seq ID No: 1, Figure 3B and Figure 5 is present in an increased amount in biological sample, such as urine, of subjects with osteoarthritis. The data also shows that a decreased level of the fibulin-3 fragment may be diagnostic of osteoporosis as well as osteoarthritis. Thus, peptides having the sequence of Seq ID No: 1, or substantially the sequence of Seq ID No: 1, or a part thereof, may be used as biomarkers for osteoarthritis, osteoporosis and/or other ageing-related diseases.
SEQUENCE LISTING

UNIVERSITE DE LIEGE

BIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF

2007-28

2

PatentIn version 3.3

1

57

PRT

Homo sapiens

1

Thr Cys Gln Asp Ile Asn Glu Cys Glu Thr Thr Asn Glu Cys Arg Glu
1 5 10 15

Asp Glu Met Cys Trp Asn Tyr His Gly Gly Phe Arg Cys Tyr Pro Arg
20 25 30

Asn Pro Cys Gln Asp Pro Tyr Ile Leu Thr Pro Glu Asn Arg Cys Val
35 40 45

Cys Pro Val Ser Asn Ala Met Cys Arg
50 55

2

493

PRT

Homo sapiens

2

Met Leu Lys Ala Leu Phe Leu Thr Met Leu Thr Leu Ala Leu Val Lys
1 5 10 15

Ser Gln Asp Thr Glu Glu Thr Ile Thr Tyr Thr Glu Cys Thr Asp Gly
20 25 30

Tyr Glu Trp Asp Pro Val Arg Gln Gln Cys Lys Asp Ile Asp Glu Cys
35 40 45

Asp Ile Val Pro Asp Ala Cys Lys Gly Gly Met Lys Cys Val Asn His
50 55 60

Tyr Gly Gly Tyr Leu Cys Leu Pro Lys Thr Ala Gln Ile Ile Val Asn
65 70 75 80
Asn Glu Gln Pro Gln Gln Glu Thr Gln Pro Ala Glu Gly Thr Ser Gly 85 90 95

Ala Thr Thr Gly Val Val Ala Ala Ser Ser Met Ala Thr Ser Gly Val 100 105 110

Leu Pro Gly Gly Gly Phe Val Ala Ser Ala Ala Ala Val Ala Gly Pro 115 120 125

Glu Met Gln Thr Gly Arg Asn Asn Phe Val Ile Arg Arg Asn Pro Ala 130 135 140

Asp Pro Gln Arg Ile Pro Ser Asn Pro Ser His Arg Ile Gln Cys Ala 145 150 155 160

Ala Gly Tyr Glu Gln Ser Glu His Asn Val Cys Gln Asp Ile Asp Glu 165 170 175

Cys Thr Ala Gly Thr His Asn Cys Arg Ala Asp Gln Val Cys Ile Asn 180 185 190

Leu Arg Gly Ser Phe Ala Cys Gln Cys Pro Pro Gly Tyr Gln Lys Arg 195 200 205

Gly Glu Gln Cys Val Asp Ile Asp Glu Cys Thr Ile Pro Pro Tyr Cys 210 215 220

His Gln Arg Cys Val Asn Thr Pro Gly Ser Phe Tyr Cys Gln Cys Ser 225 230 235 240

Pro Gly Phe Gln Leu Ala Ala Asn Tyr Thr Cys Val Asp Ile Asn 245 250 255

Glu Cys Asp Ala Ser Asn Gln Cys Ala Gln Gln Cys Tyr Asn Ile Leu 260 265 270

Gly Ser Phe Ile Cys Gln Cys Asn Gln Gly Tyr Glu Leu Ser Ser Asp 275 280 285

Arg Leu Asn Cys Glu Asp Ile Asp Glu Cys Arg Thr Ser Ser Tyr Leu 290 295 300

Cys Gln Tyr Gln Cys Val Asn Glu Pro Gly Lys Phe Ser Cys Met Cys 305 310 315 320

Pro Gln Gly Tyr Gln Val Val Arg Ser Arg Thr Cys Gln Asp Ile Asn 325 330 335
EP 2 975 411 A1

Glu Cys Glu Thr Thr Asn Glu Cys Arg Glu Asp Glu Met Cys Trp Asn 340

345

350

Tyr His Gly Gly Phe Arg Cys Tyr Pro Arg Asn Pro Cys Gln Asp Pro 355

360

365

Tyr Ile Leu Thr Pro Glu Asn Arg Cys Val Cys Pro Val Ser Asn Ala 370

375

380

Met Cys Arg Glu Leu Pro Gln Ser Ile Val Tyr Lys Tyr Met Ser Ile 385

390

395

400

Arg Ser Asp Arg Ser Val Pro Ser Asp Ile Phe Gln Ile Gln Ala Thr 405

410

415

Thr Ile Tyr Ala Asn Thr Ile Asn Thr Phe Arg Ile Lys Ser Gly Asn 420

425

430

Glu Asn Gly Glu Tyr Leu Arg Gln Thr Ser Pro Val Ser Ala Met 435

440

445

Leu Val Leu Val Lys Ser Leu Ser Gly Pro Arg Glu His Ile Val Asp 450

455

460

Leu Glu Met Leu Thr Val Ser Ser Ile Gly Thr Phe Arg Thr Ser Ser 465

470

475

480

Val Leu Arg Leu Thr Ile Ile Val Gly Pro Phe Ser Phe 485

490

Claims

1. A method of diagnosing osteoarthritis and/or another ageing-related disease in a subject, comprising the steps of:

(i) determining the concentration in a biological sample of a peptide fragment consisting of an amino acid sequence of first through fifteen and/or forty seventh through fifty seventh amino acids of Seq ID no:1;

(ii) comparing the peptide fragment concentration determined in step (i) with one or more reference value;

wherein an increase in the concentration of the peptide fragment compared to the reference values is diagnostic of osteoarthritis and/or another ageing-related disease.

2. A method of determining the prognosis for a subject with osteoarthritis and/or another ageing-related disease, comprising the steps of:

(i) determining the concentration in a biological sample of a peptide fragment consisting of an amino acid sequence of first through fifteen and/or forty seventh through fifty seventh amino acids of Seq ID no:1;

(iii) comparing the peptide fragment concentration determined in step (i) with one or more reference values;

wherein an increase in the concentration of the peptide fragment compared to the reference values is prognostic of osteoarthritis and/or another ageing-related disease.
3. The method of any preceding claim wherein the biological sample is selected from the group comprising urine, whole blood, blood serum, blood plasma, synovium, sweat, cerebrospinal fluid, mucous, saliva, lymph, bronchial aspirates and milk.

4. The method of any preceding claim wherein the concentration of the peptide fragment is determined by using mass spectrometry or an immunoassay.

5. The method of any preceding claim wherein the reference value is the concentration of the peptide fragment in one or more normal subjects.

6. A kit for use in diagnosing osteoarthritis and/or another ageing-related disease in a subject or in determining the prognosis for a subject with osteoarthritis and/or another ageing-related disease, said kit comprising at least one agent for determining the concentration of a peptide fragment consisting of an amino acid sequence of first through fifteen and/or forty seventh through fifty seventh amino acids of Seq ID no:1, in a biological sample.

7. The kit according to claim 6 wherein the agent is selected from the group comprising an enzyme, an antibody, a protein probe, a metabolite or any other suitable composition.

8. The kit according to claim 6 or 7 wherein the agent comprises two antibodies directed to different epitopes on the peptide fragment.

9. The kit according to claim 8 for use in determining the concentration of the peptide fragment by using a sandwich immunoassay.

10. An isolated peptide fragment consisting of an amino acid sequence of first through fifteen and/or forty seventh through fifty seventh amino acids of Seq ID no:1, or its amide, or a salt thereof.

11. A polynucleotide encoding a peptide fragment according to claim 10.

12. A recombinant vector comprising a polynucleotide according to claim 11.

13. A transformant transformed with a recombinant vector according to claim 12.

14. Use of a peptide fragment according to claim 10 in the manufacture of an antibody.

15. An antibody specific for a peptide fragment according to claim 10.
### Figure 3A

<table>
<thead>
<tr>
<th>Query</th>
<th>Observed</th>
<th>Mr(expt)</th>
<th>Mr(calc)</th>
<th>Delta</th>
<th>Miss</th>
<th>Score</th>
<th>Expect</th>
<th>Rank</th>
<th>Peptide</th>
</tr>
</thead>
<tbody>
<tr>
<td>149</td>
<td>685.33</td>
<td>1368.64</td>
<td>1368.54</td>
<td>0.09</td>
<td>0</td>
<td>58</td>
<td>0.00027</td>
<td>1</td>
<td>R.CVFVENVAMCR.E</td>
</tr>
<tr>
<td>464</td>
<td>965.32</td>
<td>1928.63</td>
<td>1928.73</td>
<td>-0.10</td>
<td>0</td>
<td>72</td>
<td>4.2e-06</td>
<td>1</td>
<td>R.TCQDINECCPTNCFR.E</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>20</td>
<td>30</td>
<td>40</td>
<td>50</td>
<td>60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NLKAL</td>
<td>FTL</td>
<td>L</td>
<td>T</td>
<td>IA</td>
<td>LVK</td>
<td>SQD</td>
<td>T</td>
<td>ET</td>
<td>SITY</td>
</tr>
<tr>
<td>CVNH</td>
<td>YNG</td>
<td>GY</td>
<td>L</td>
<td>C</td>
<td>LP</td>
<td>K</td>
<td>I</td>
<td>AQ</td>
<td>II</td>
</tr>
<tr>
<td>130</td>
<td>140</td>
<td>150</td>
<td>160</td>
<td>170</td>
<td>180</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAA</td>
<td>VAPGE</td>
<td>P</td>
<td>M</td>
<td>QT</td>
<td>GR</td>
<td>NN</td>
<td>PV</td>
<td>I</td>
<td>R</td>
</tr>
<tr>
<td>190</td>
<td>200</td>
<td>210</td>
<td>220</td>
<td>230</td>
<td>240</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNCRA</td>
<td>DQ</td>
<td>VC</td>
<td>I</td>
<td>LG</td>
<td>G</td>
<td>SF</td>
<td>AC</td>
<td>Q</td>
<td>CPP</td>
</tr>
<tr>
<td>250</td>
<td>260</td>
<td>270</td>
<td>280</td>
<td>290</td>
<td>300</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FGV</td>
<td>GLA</td>
<td>AN</td>
<td>NT</td>
<td>TC</td>
<td>VD</td>
<td>INE</td>
<td>DC</td>
<td>R</td>
<td>S</td>
</tr>
<tr>
<td>310</td>
<td>320</td>
<td>330</td>
<td>340</td>
<td>350</td>
<td>360</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSY</td>
<td>LCO</td>
<td>Q</td>
<td>Y</td>
<td>QC</td>
<td>NE</td>
<td>PG</td>
<td>KH</td>
<td>F</td>
<td>SC</td>
</tr>
<tr>
<td>370</td>
<td>380</td>
<td>390</td>
<td>400</td>
<td>410</td>
<td>420</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNN</td>
<td>FCQ</td>
<td>DP</td>
<td>PYI</td>
<td>LT</td>
<td>PE</td>
<td>NR</td>
<td>VC</td>
<td>CV</td>
<td>RP</td>
</tr>
<tr>
<td>430</td>
<td>440</td>
<td>450</td>
<td>460</td>
<td>470</td>
<td>480</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NTT</td>
<td>IN</td>
<td>FR</td>
<td>IS</td>
<td>C</td>
<td>H</td>
<td>M</td>
<td>E</td>
<td>FY</td>
<td>I</td>
</tr>
<tr>
<td>490</td>
<td>VLR</td>
<td>T</td>
<td>I</td>
<td>TV</td>
<td>G</td>
<td>PS</td>
<td>TS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 3B
Figure 4

Figure 5
TCQDINECETTNECREDEMCMWNYHGGRFRCYPNPRCQDPYILTPENRCVCPVSNAMCR

Figure 6
MLKALFLTMLTLALVKSQDTEETITYTQTCTDGYEWDPRQCPPKDIDECDIVPDAACKGGMKCVNHGYYLCLPKTAQIIIVNNEQPQQETQPAGETGNGTVVAASSMATSGVLPGGGFPASAAAVAGPEMQTGRNNFVIRRNPADQRIPSNPSHRIRQCAAGYEQSEHNVCQDIETACTAGTHNCRADQCINLRGSFACQCPPGYQKRGEQCVDIETCTIPYCHQRVCNTPGSFYQCSCPQFLAANNYTCVDINECDASNQCAQQCNYILGSICQCNCQNGYELSSDRLNCEDIDECTSSYCQYCVNEPGKFSMCpqgyqVVRSTCQDINECETTNECREDEMCMWNYHGGRFRCYPNPRCQDPYILTPENRCVCPSVSNAMCRLEPQSVICYKMISRSDRVSVPDISFQIQATTIYANTINTFRKSGNENGEFYLRQTSPVSAMLVLVKSLSGPREHVIDLEMLTVSSIGTFRTSSVLRLLTIVGPFSF
Figure 8

* Increase of OA/OP ratio

* Increase of OA/CTRL ratio
# DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2008/012362 A2 (OXFORD GENOME SCIENCES UK LTD [GB]; ROHLFF CHRISTIAN [GB]) 31 January 2008 (2008-01-31) * page 100, paragraph 4; table 1; sequences 56,351 *</td>
<td>6-15</td>
<td>INV. G01N33/68 C07K16/44</td>
</tr>
</tbody>
</table>

---

The present search report has been drawn up for all claims.

The Hague 13 October 2015

Wiesner, Martina

---

**CATEGORY OF CITED DOCUMENTS**

- **X**: particularly relevant cited alone
- **Y**: particularly relevant if combined with another document of the same category
- **A**: technological background
- **D**: non-written disclosure
- **P**: intermediate document

**CLASSIFICATION OF THE APPLICATION (IPC)**

- **INV.**: Invention
- **G01N**: Measurement of forces between objects
- **C07K**: Analytical or Chemical analysis
- **GOIN**: Other groups

---

**Filing Date**

13 October 2015
**DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>* claims 1-3, 5-6; sequence 3264 *</td>
<td></td>
<td>----</td>
</tr>
<tr>
<td>A</td>
<td>WO 03/063689 A (QUARK BIOTECH INC [US]; SHIONOGI &amp; CO [JP]; SEGEV ORIT [IL]; FEINSTEIN) 7 August 2003 (2003-08-07)</td>
<td>1-15</td>
<td>----</td>
</tr>
<tr>
<td>A</td>
<td>* claim 33 *</td>
<td></td>
<td>----</td>
</tr>
<tr>
<td>A</td>
<td>WO 2006/138646 A (B RiGHAM &amp; WOMENs HOSPITAL [US]; MILLETT PETER J [US]; SARRACINO DAVID) 28 December 2006 (2006-12-28)</td>
<td>1-15</td>
<td>----</td>
</tr>
<tr>
<td>A</td>
<td>* claims 1, 6, 7 *</td>
<td></td>
<td>----</td>
</tr>
<tr>
<td>A</td>
<td>* page 3676, right-hand column, paragraph 3; figure 5; table 1 *</td>
<td></td>
<td>----</td>
</tr>
<tr>
<td>A</td>
<td>* page 3682, right-hand column, paragraph 3 *</td>
<td></td>
<td>----</td>
</tr>
</tbody>
</table>

The present search report has been drawn up for all claims

<table>
<thead>
<tr>
<th>Place of search</th>
<th>Date of completion of the search</th>
<th>Examiner</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Hague</td>
<td>13 October 2015</td>
<td>Wiesner, Martina</td>
</tr>
</tbody>
</table>

**CATEGORY OF CITED DOCUMENTS**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>particularly relevant if taken alone</td>
</tr>
<tr>
<td>Y</td>
<td>particularly relevant if combined with another document of the same category</td>
</tr>
<tr>
<td>Z</td>
<td>technological background</td>
</tr>
<tr>
<td>D</td>
<td>non-written disclosure</td>
</tr>
<tr>
<td>P</td>
<td>intermediate document</td>
</tr>
<tr>
<td>T</td>
<td>theory or principle underlying the invention</td>
</tr>
<tr>
<td>E</td>
<td>earlier patent document, but published on, or after the filing date</td>
</tr>
<tr>
<td>A</td>
<td>document cited in the application</td>
</tr>
<tr>
<td>L</td>
<td>document cited for other reasons</td>
</tr>
<tr>
<td>A</td>
<td>member of the same patent family, corresponding document</td>
</tr>
</tbody>
</table>

24
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of relevant passages</th>
<th>Relevant to claim</th>
<th>CLASSIFICATION OF THE APPLICATION (IPC)</th>
</tr>
</thead>
</table>

The present search report has been drawn up for all claims

Place of search: The Hague
Date of completion of the search: 13 October 2015
 Examiner: Wiesner, Martina

CATEGORY OF CITED DOCUMENTS
X: particularly relevant if taken alone
Y: particularly relevant if combined with another document of the same category
A: technologically background
D: non-written disclosure
P: intermediate document
T: theory or principle underlying the invention
E: earlier patent document, but published on, or after the filing date
D: document cited in the application
L: document cited for other reasons
A: member of the same patent family, corresponding document
This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EPO file on the European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-10-2015

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>US 2009208507 A1</td>
<td>20-08-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2008012362 A2</td>
<td>31-01-2008</td>
</tr>
<tr>
<td>WO 2006006477 A</td>
<td>19-01-2006</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2613813 A1</td>
<td>11-01-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 101258240 A</td>
<td>03-09-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20060032139 A</td>
<td>14-04-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010058488 A1</td>
<td>04-03-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2006004066 A1</td>
<td>12-01-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2007004325 A1</td>
<td>11-01-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2003236392 A1</td>
<td>25-12-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2006029945 A1</td>
<td>09-02-2006</td>
</tr>
<tr>
<td>WO 03063689 A</td>
<td>07-08-2003</td>
<td>AU 2003207738 A1</td>
<td>02-09-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 200508491 A1</td>
<td>21-01-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2007243186 A1</td>
<td>18-10-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 03063689 A2</td>
<td>07-08-2003</td>
</tr>
<tr>
<td>WO 2006138646 A</td>
<td>28-12-2006</td>
<td>AU 2006261641 A1</td>
<td>28-12-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2615947 A1</td>
<td>28-12-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1894016 A2</td>
<td>05-03-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2008547066 A</td>
<td>25-12-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2010935374 A</td>
<td>12-04-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010292154 A1</td>
<td>18-11-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2006138646 A2</td>
<td>28-12-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2006052735 A2</td>
<td>18-05-2006</td>
</tr>
</tbody>
</table>

For more details about this annex: see Official Journal of the European Patent Office, No. 12/2015
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **PAPPIN et al.** *Curr Biol*, 01 June 1993, vol. 3 (6), 327-32 [0066]